Search results

Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over

Type

Highly specialised technologies guidance

Published

06 July 2022

Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

Type

Highly specialised technologies guidance

Published

05 May 2022

Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages

Type

Highly specialised technologies guidance

Published

20 April 2022

Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children

Type

Highly specialised technologies guidance

Published

28 March 2022

This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.

Type

Antimicrobial prescribing guideline

Last updated

11 March 2022

Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older

Type

Highly specialised technologies guidance

Published

22 February 2022

Evidence-based recommendations on givosiran (Givlaari) for treating acute hepatic porphyria in adults and young people aged 12 and over

Type

Highly specialised technologies guidance

Published

24 November 2021

This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.

Type

Antimicrobial prescribing guideline

Published

23 July 2021

Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating spinal muscular atrophy in babies

Type

Highly specialised technologies guidance

Published

07 July 2021

This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.

Type

Antimicrobial prescribing guideline

Published

02 March 2021

Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults

Type

Highly specialised technologies guidance

Published

24 February 2021

This guideline sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

04 November 2020

Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults

Type

Highly specialised technologies guidance

Published

21 October 2020

This guideline sets out an antimicrobial prescribing strategy for insect and spider bites and stings in adults, young people and children aged 72 hours and over, including those that occurred while travelling outside the UK. It aims to limit antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

22 September 2020

This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

26 February 2020

This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

11 February 2020

Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

Type

Highly specialised technologies guidance

Published

27 November 2019

This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.

Type

NICE guideline

Last updated

11 October 2019

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

Type

Highly specialised technologies guidance

Published

09 October 2019

This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

27 September 2019

This guideline sets out an antimicrobial prescribing strategy for community-acquired pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

16 September 2019

This guideline sets out an antimicrobial prescribing strategy for hospital-acquired pneumonia. It does not cover ventilator-associated pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

16 September 2019

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Type

Highly specialised technologies guidance

Published

14 August 2019

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Type

Highly specialised technologies guidance

Published

22 May 2019

This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

07 February 2019

This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

18 December 2018

This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

05 December 2018

This guideline sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

23 November 2018

This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

31 October 2018

This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

31 October 2018

This guideline sets out an antimicrobial prescribing strategy for lower urinary tract infection (also called cystitis) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

31 October 2018

This guideline sets out an antimicrobial prescribing strategy for acute prostatitis. It aims to optimise antibiotic use and reduce antibiotic resistance.

Type

Antimicrobial prescribing guideline

Published

31 October 2018

Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

Type

Highly specialised technologies guidance

Published

10 October 2018

Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency

Type

Highly specialised technologies guidance

Published

07 February 2018

This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

Type

Antimicrobial prescribing guideline

Published

26 January 2018

This guideline sets out an antimicrobial prescribing strategy for acute sinusitis. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sinusitis is usually caused by a virus, lasts for about 2 to 3 weeks, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

Type

Antimicrobial prescribing guideline

Published

27 October 2017

Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

Type

Highly specialised technologies guidance

Published

02 August 2017

Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults

Type

Highly specialised technologies guidance

Published

28 June 2017

This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.

Type

NICE guideline

Published

30 March 2017

This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.

Type

Medicines practice guideline

Last updated

27 March 2017

Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16

Type

Highly specialised technologies guidance

Published

22 February 2017

Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged

Type

Highly specialised technologies guidance

Published

20 July 2016

This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.

Type

NICE guideline

Published

12 April 2016

This guidance has been updated and replaced by NICE’s highly specialised technologies guidance on elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19).

Type

Highly specialised technologies guidance

Published

16 December 2015

This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.

Type

Medicines practice guideline

Last updated

28 October 2015

This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.

Type

NICE guideline

Published

18 August 2015

This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

Type

NICE guideline

Published

27 February 2015

Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children

Type

Highly specialised technologies guidance

Published

28 January 2015

This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.

Type

Safe staffing guideline

Published

15 July 2014

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development